Meningiomas are common, often indolent, primary brain tumors. Unfortunately, once maximum safe resection and radiation options are exhausted, patients with progression or recurrence are left with few remaining effective therapies. Angiogenesis via VEGF-mediated pathways is felt to be an etiology for progression of these tumors, making it a reasonable target for therapy. We performed a retrospective review of adult patients managed with bevacizumab (BEV) for recurrent or progressive meningiomas between 2011-2016. Seven patients, three with progressive grade I meningiomas and four with recurrent grade II atypical meningiomas, were treated with BEV. Median KPS for included patients was 90. Dosing schedules varied, but usually consisted of 10 mg/kg IV every 2 weeks. Mean exposure to BEV was approximately 16 months (6 months to 44 months). Of note, two patients were treated for over 2 years with BEV, and each developed proteinuria which caused treatment cessation. Off BEV, both patients have remained radiographically stable. In contrast, four patients were treated with 6 cycles of BEV at 10 mg/kg IV every 2 weeks, followed by observation. Three of those patients had initial partial responses, and all six of them currently have stable disease. PFS for progressive grade I meningiomas was 33.5 months, and all patients are still living. PFS for recurrent grade II meningiomas was 21.1 months, and one patient died from complications felt to be unrelated to BEV. Therapy was well-tolerated in the group which received six cycles. One patient had a CVA which was felt to be radiation-induced. Other retrospective series examining BEV in patients with recurrent/ progressive meningiomas tend to favor prolonged exposure to BEV and have confirmed bleeding complications such as intracerebral hemorrhage or gastrointestinal perforation. We favor a more conservative approach, planning for an initial 6 month course, followed by observation if patients are clinically and radiographically stable.